|
Match
|
Document |
Document Title |
|
|
US20170029437 |
Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders
The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET... |
|
|
US20160193152 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the... |
|
|
US20160038508 |
PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS
The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. |
|
|
US20160022574 |
NON-MUCOADHESIVE FILM DOSAGE FORMS
Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the... |
|
|
US20150224130 |
Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one... |
|
|
US20150064118 |
LIPID DEPOT FORMULATIONS
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least... |
|
|
US20140107107 |
PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS
A solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula (1) wherein X is a halogen, R1 is C1-C4 alkyl, R2 is C1-C4 alkyl, a is an integer of 1-4, R3 is C1-C4... |
|
|
US20130236573 |
ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a... |
|
|
US20110300210 |
CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20100260858 |
DRUG DELIVERY COMPOSITION
A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 μm and... |
|
|
US20100063010 |
METHOD FOR ADMINISTERING A SPILL RESISTANT PHARMACEUTICAL SYSTEM
A method for administering a spill-resistant pharmaceutical formulation comprises delivery from a squeezable container of a pharmaceutical agent in a suitable vehicle comprising a liquid base and... |
|
|
US20090297619 |
NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20080248123 |
Nanoparticulate anticonvulsant and immunosuppressive compositions
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20070105843 |
COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST
The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic... |
|
|
US20060111307 |
Methods and compositions for treating pain
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux... |
|
|
US20050119160 |
Methods and reagents for the treatment of immunoinflammatory disorders
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted... |
|
|
US20050014743 |
Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a... |
|
|
US20160045504 |
COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA
The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion... |
|
|
US20150283092 |
DRUG DELIVERY COMPOSITION
A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 μm and... |
|
|
US20150210706 |
Benzodiazepine Bromodomain Inhibitor
The present invention relates to a benzodiazepine compound, processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy. |
|
|
US20140206667 |
METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and... |
|
|
US20140051689 |
Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections
Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl... |
|
|
US20140038935 |
DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of... |
|
|
US20120003330 |
BENZOQUINOLONE INHIBITORS OF VMAT2
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. |
|
|
US20100260859 |
CONTROLLED-RELEASE CLOZAPINE COMPOSITIONS
A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of clozapine having an effective average particle size of less than or about 2 μm and at... |
|
|
US20100189762 |
TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and... |
|
|
US20090186099 |
BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in... |
|
|
US20090018119 |
USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE
Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a... |
|
|
US20070219243 |
Method for improving the pharmacokinetics of HIV integrase inhibitors
The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with... |
|
|
US20060276412 |
METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS
Compositions for treating psychotic disorders comprise a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group... |
|
|
US20060069086 |
Methods for regulating neurotransmitter systems by inducing counteradaptations
The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a... |
|
|
US20050181049 |
Composition and method for enhancing bioavailability
The present invention relates to compositions and methods for enhancing the bioavailability of beneficial agents with low water solubility. |
|
|
US20170166562 |
BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. |
|
|
US20170145021 |
NOVEL COMPOUNDS
Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy. |
|
|
US20160158220 |
BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. |
|
|
US20140128378 |
METHODS OF TREATING EPILEPTOGENESIS
The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus. |
|
|
US20120027879 |
BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING METABOLIC DISORDERS
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in... |
|
|
US20110046117 |
COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence... |
|
|
US20100113427 |
COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence... |
|
|
US20100113426 |
Intranasal Benzodiazepine Compositions
A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt... |
|
|
US20080004260 |
Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence... |
|
|
US20070172469 |
Methods For Inhibiting Viral Replication In Vivo
The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a... |
|
|
US20070160668 |
Prolonged release bioadhesive therapeutic systems
The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over... |
|
|
US20070087977 |
METHODS AND COMPOSITIONS FOR TREATING PAIN
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux... |
|
|
US20060040922 |
Aripiprazole, olanzapine and haloperidol pamoate salts
The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the... |
|
|
US20160346270 |
BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. (Formula (I)) |
|
|
US20160279141 |
COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS
The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs. |
|
|
US20160074415 |
METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising... |
|
|
US20160024011 |
Multi-API Loading Prodrugs
The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed... |
|
|
US20150164802 |
Methods for the preparation of biologically active compounds in nanoparticulate form
A method for producing a composition comprising nanoparticles of a biologically active compound. |